EDROPHONIUM CHLORIDE


Trade Names	EDROPHONIUM CHLORIDE EDROPHONIUM CHLORIDE PRESERVATIVE FREE ENLON REVERSOL TENSILON TENSILON PRESERVATIVE FREE
Synonyms	Antirex Camsilon Edrophone chloride Edrophonii chloridum Edrophonium Chloride Edrophonium chloride Edrophonium chloride preservative free Enlon NSC-759577 Reversol Tensilon Tensilon preservative free
Status
Molecule Category	Salt
UNII	QO611KSM5P
EPA CompTox	DTXSID1022978


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BXKDSDJJOVIHMX-UHFFFAOYSA-N
Smiles	CC[N+](C)(C)c1cccc(O)c1.[Cl-]
InChI	InChI=1S/C10H15NO.ClH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H16ClNO
Molecular Weight	201.7
AlogP	1.98
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	20.23
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	12.0

Pharmacology

Mechanism of Action	Action	Reference
Acetylcholinesterase inhibitor	INHIBITOR	DailyMed


Protein: Acetylcholinesterase Description: Acetylcholinesterase Organism : Homo sapiens P22303 ENSG00000087085

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	200-5170	-	200-4800	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	79

Cross References

Resources	Reference
ChEBI	4759
ChEMBL	CHEMBL1128
FDA SRS	QO611KSM5P
PubChem	8307
SureChEMBL	SCHEMBL34789

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).